Kardigan

Drug Discovery · South San Francisco, CA · Founded 2023 · Privately Held (backing)

Operator of a heart health company intended to modernize cardiovascular drug development. Kardigan is based in South San Francisco, CA and was founded in 2023. It is valued at about $646 million as of Oct 2026, set by institutional fund marks. It has raised $554 million across 1 recorded round; the latest was a $254 million Series B in Oct 2025.

PMV mark · valuation
$646.0M
Oct 2026
Priced at
—
Total raised
$554.0M
Last round
Early Stage VC (Series B)
Oct 2025
What is Kardigan worth?
$646.0MPrivateMarketView mark · Oct 2026

Reported valuation; nothing comparable since.

Pro
The prices on Kardigan
  • ·6 fund marks: filer, period, implied $/share
Pro · $99 a month
List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Kardigan funding history

1 rounds
DateRoundRaisedPost-money
Oct 2025Early Stage VC (Series B)$254.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Kardigan valuation

Kardigan is valued at approximately $646 million as of Oct 2026. The figure is set by institutional fund marks.

Recent activity

In the last 90 days, Kardigan's record added 3 institutional fund marks (latest period Jul 2026).

How much has Kardigan raised?

Kardigan has raised $554 million in total; 1 of its rounds is on record. The largest on record was a $254 million Series B in Oct 2025.

Institutional holders and vehicles

2 SEC-registered funds reported 6 fair-value marks on Kardigan between Nov 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Abcuro ($700 million), Candid Therapeutics ($657 million) and VeraDermics (NYS: MANE) ($596 million).

How Kardigan's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Kardigan, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by institutional fund marks. Question about this number? Full methodology →

Frequently asked about Kardigan

What is Kardigan worth?
Kardigan is valued at $646.0M as of Oct 2026. Reported valuation; nothing comparable since.
How much has Kardigan raised?
Kardigan has raised $554.0M in total funding across 1 recorded rounds.
When did Kardigan last raise?
Kardigan last raised in Oct 2025 (Early Stage VC (Series B)), raising $254.0M.